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Abstract: Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory cytokine
tumor necrosis factor-α (TNF-α) are associated with disease activity and severity. Anti-TNF-α therapy
is administered systemically and efficacious in the treatment of IBD. However, systemic exposure is
associated with adverse events that may impede therapeutic treatment. Clinical studies show that the
efficacy correlates with immunological effects localized in the gastrointestinal tract (GIT) as opposed to
systemic effects. These data suggest that site-specific TNF-α inhibition in IBD may be efficacious with
fewer expected side effects related to systemic exposure. We therefore reviewed the available literature
that investigated the efficacy or feasibility of local TNF-α inhibition in IBD. A literature search was
performed on PubMed with given search terms and strategy. Of 8739 hits, 48 citations were included in
this review. These studies ranged from animal studies to randomized placebo-controlled clinical trials.
In these studies, local anti-TNF-α therapy was achieved with antibodies, antisense oligonucleotides
(ASO), small interfering RNA (siRNA), microRNA (miRNA) and genetically modified organisms.
This narrative review summarizes and discusses these approaches in view of the clinical relevance of
local TNF-α inhibition in IBD.
Keywords: inflammatory bowel disease; tumor necrosis factor-α; local; topical; site-specific; drug
targeting; antibody; antisense; miRNA; prokaryote; eukaryote
1. Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are immune-mediated types of inflammatory
bowel diseases (IBD) affecting the gastrointestinal tract (GIT). IBD is a chronic disease with a course
characterized by remission and relapse. Disease symptoms include chronic diarrhea, abdominal pain,
weight loss and bloody stools. The severity combined with the chronic nature of the disease results
in a decreased health-related quality of life, disability and frequent hospitalizations. Whereas the
continuous and diffuse inflammation of the mucosa in UC is typically limited to the rectum and
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may extent proximally, the granulomatous transmural inflammation in CD affect most commonly the
ileo-colonic region [1–3].
Although the exact pathogenesis of IBD is unclear, research shows that a combination of genetics,
environmental factors and the microbiome play a prominent role in the onset of gut epithelial
dysfunction. Consequently, increased exposure of the gut wall to luminal antigens trigger an aberrant
acute inflammatory response driven by the innate immune system. Secretion of proinflammatory
cytokines such as interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) results not only in
tissue damage, but the activation of the adaptive immune system as well. Tissue damage in turn may
result in an increased exposure of the gut wall to luminal antigens inducing a stronger activation of
both the innate and adaptive immune system, which perpetuates the inflammatory state resulting in
chronic inflammation (Figure 1) [2–7].
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Figure 1. Mucosal immunology of the gastrointestinal tract (GIT) under homeostasis, acute inflammation
and chronic inflammation in inflammatory bowel diseases (IBD). The aberrant immunological response
of the innate immune system induces an acute inflammatory state that may progress to chronic
inflammation with a prominent role of the adaptive immune system. The involved cytokine network is
complex and shows a major role of the proinflammatory cytokine tumor necrosis factor-α (TNF-α).
For an explanation and overview of all the abbreviations, the reader is referred to the original work of
this Figure [4]. Reprinted from Friedrich et al. [4] with permission from Elsevier.
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TNF-α is a pleiotropic proinflammatory cytokine implicated in a wide range of cellular processes
including cell proliferation, survival and death. In addition, TNF-α signaling is associated with the
regulation of several inflammatory pathways including the cyclooxygenase-2 (COX-2) and inducible
nitric oxide synthase (iNOS) pathways [8–11]. Hence, TNF-α is a key mediator in the inflammatory
response. TNF-α is predominantly secreted by monocytes, macrophages and natural killer cells [12–16].
TNF-α is first synthesized as a transmembrane protein (tmTNF-α) and can induce immunological
responses in effector cells, but also transduce reverse signaling by contact-dependent cell interactions.
In addition, tmTNF-α can be enzymatically cleaved by TNF-α-converting enzyme (TACE) resulting in
soluble TNF-α (sTNF-α). Upon distribution in the extracellular space or systemic circulation, sTNF-α
may exert immunological effects at distant sites. Therefore, both forms are active cytokines that
share similar as well as distinctive immunological effects. TNF-α activation of effector cells under
physiological conditions generally leads to a proinflammatory response or apoptosis and aids in the
defense against infections and localized tissue injury [12–16]. However, the elevated TNF-α tissue
levels in the mucosa and lamina propria of IBD patients result in an aberrant proinflammatory response
that is associated with the dysregulation of mucosal immune cells and tissue damage [4,7].
Anti-TNF-α therapy aims to antagonize the effects of TNF-α. Examples of anti-TNF-α therapies
which are or have been used in the clinical setting of IBD are infliximab (IFX), adalimumab, golimumab,
certolizumab, etanercept, onercept and CDP571 (Figure 2). These biologicals are antibodies or soluble
TNF-α receptors (sTNFR) that neutralize TNF-α. Although the main mechanism of action is TNF-α
antagonism, these drugs have distinctive pharmacodynamic profiles that are specific for the individual
compound partly due to the variations in the molecular structure. Hence, the observed efficacy
of the different anti-TNF-α therapies in IBD vary and are not equivalent (reviewed in: [13,17–22]).
The desired therapeutic effects include a sustained anti-inflammatory response, mucosal healing and
restoration of the gut epithelial barrier function [23,24]. However, anti-TNF-α therapy is associated with
adverse events related to systemic exposure. These adverse events include infusion reactions [25,26],
psoriasis or psoriasiform lesions [27], osteonecrosis of the jaw [28,29], the development of antinuclear
antibodies (ANA) [30–33] and an increased risk of opportunistic infections [34–36] and developing
lymphoma [37]. Additionally, infusion reactions are associated with therapy discontinuation [38].
Systemic administration may induce anti-drug antibodies (ADA), which in turn is associated with
infusion reactions as well as loss of efficacy [39–41].
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Research shows that the local immunological environment in the GIT correlates with IBD
disease activity [42–45], type [46–48] and relapse [49,50]. Furthermore, studies investigating the
local immunological environment of the GIT before and after anti-TNF-α therapy show that
the therapy reduces histological and endoscopical disease activity [51–53], inhibits activation of
immune cells [54–56], downregulates the expression of cell adhesion molecules and proinflammatory
cytokines [53,57–62], modulates apoptosis of monocytes as well as enterocytes [63], restores gut
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barrier function [64,65] and levels of antimicrobial peptides [66] and has a favorable effect on the
gut microbiome [67–69]. Importantly, it was shown that anti-TNF-α therapy induces a potent local,
but not a systemic effect [70] and that gut tissue concentrations may correlate better with a clinical
and sustained response compared to serum levels alone [71,72]. This may partly explain anti-TNF-α
therapy failure despite therapeutic drug concentrations. Collectively these observations suggest
that local as opposed to systemic TNF-α inhibition may be an efficacious treatment option for IBD
which may have fewer adverse events related to systemic exposure. However, major challenges in
accomplishing site-specific TNF-α inhibition with macromolecules such as proteins are drug targeting
and the subsequent stability of the drug in the GIT. More important, drug penetration into the targeted
inflamed sites is a prerequisite for drug efficacy, but may arguably impose the biggest challenge since
the absorption mechanisms and kinetics of macromolecules differ substantially from smaller chemical
entities [73–78].
The objective of this narrative review was to evaluate the available literature on PubMed with
regards to local TNF-α inhibition in IBD. First, animal studies investigating the efficacy or feasibility
of local TNF-α inhibition in IBD are discussed. These studies investigated formulations containing
antibodies, antisense oligonucleotides (ASO), small interfering RNA (siRNA), microRNA (miRNA) and
genetically modified organisms. Subsequently, clinical studies ranging from case reports to randomized
placebo-controlled clinical trials that investigated the efficacy or feasibility of local TNF-α inhibition in
IBD are discussed. This review aims to summarize the available literature on local TNF-α inhibition
with macromolecules intended for the treatment of IBD.
2. Methods
This is a narrative review. However, in view of finding relevant citations in the medical literature,
the following search strategy was used on PubMed. The search term for citations with regards to local
biologic therapy was ”(tumor necrosis factor OR TNF OR tumor necrosis factor inhibitor OR TNF
inhibitor OR anti-tumor necrosis factor OR anti TNF OR infliximab OR adalimumab OR certolizumab
pegol OR golimumab OR etanercept OR onercept OR humicade OR CDP571) AND (local OR locally
OR tissue OR intralesional OR intralesionally OR site specific OR direct OR directly OR topical OR
topically OR targeted OR target OR targeting OR rectal OR rectally OR enema OR suppository OR oral
OR orally OR colonic OR colon OR ileum OR ileo-colonic OR mucosa OR mucosal) AND (Crohn’s
disease OR inflammatory bowel disease OR ulcerative colitis OR proctitis OR pancolitis OR colitis
OR IBD)”. This yielded 8339 hits, published from June 1985–May 2020. The citations published up to
1 May 2020 were included in this review.
The search term for citations with regards to gene-silencing therapy was “(gene silencing OR
antisense OR RNA silencing OR small interfering RNA OR siRNA OR oligonucleotide OR antisense
oligonucleotide) AND (tumor necrosis factor OR tumor necrosis factor-alpha OR TNF) AND (Crohn’s
disease OR inflammatory bowel disease OR ulcerative colitis OR proctitis OR pancolitis OR colitis OR
IBD)”. This yielded 400 hits, published between July 1993–May 2020. The citations published up to
1 May 2020 were included in this review.
All the titles and abstracts of the citations were read. The reference sections of the included
citations were read for additional relevant citations that could be included in this review. Citations
that investigated local TNF-α inhibition in human or animal studies were included. Studies that
investigated systemically administered anti-TNF-α therapy with experiments aimed to elucidate the
local effects in gastrointestinal (GI) regions were included as well. Citation that conducted in vitro
studies without any in vivo investigations were excluded.
Out of a total of 8739 citations, 31 animal studies are summarized in Table 1 and discussed in
Section 3. Preclinical studies on local TNF-α inhibition and 17 clinical studies are summarized in Table
2 and discussed in Section 4. Clinical studies on local TNF-α inhibition. Section 3. predominantly
reviews experimental therapy and formulation strategies that aim to target the localized inflammation
sites in the GIT in IBD animal models. Section 4. reviews the available clinical studies that investigated
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the efficacy or feasibility of local TNF-α inhibition in IBD. In view of readability we used the word
‘significant’ to depict a ‘statistically significant effect’ whereas ‘significant’ was not used to discuss
experiments that showed a remarkable effect without statistical significance or on which no statistics
were performed at all by the authors of the original citations.
3. Preclinical Studies on Local TNF-α Inhibition
3.1. Considerations
Anti-TNF-α formulations have been investigated in animal models (Table 1). These animal models
were predominantly chemically induced colitis models in mice though some studies investigated the
formulations in genetically induced colitis models or healthy animals. The most commonly used colitis
models for IBD research were dextran sulfate sodium (DSS)- and 2,4,6-trinitrobenzenesulfonic acid
(TNBS)-induced chemical colitis models, which share resembles with UC and CD, respectively [79,80].
Several antibodies were investigated in IBD animal models in the context of local TNF-α inhibition.
These antibodies were or were not produced by a host carrier. For instance, prokaryotic or eukaryotic
carriers of a vector that produce anti-TNF-α antibodies may secrete the antibody in the GIT of the host
in view of local TNF-α inhibition. Alternatively, the carrier may be used to deliver a vector to gut
epithelial cells that express the protein after genetic transformation. These complex processes impose
great challenges in order to achieve reproducible and therapeutic local TNF-α inhibition since drug
levels are dependent on many factors that are variable such as the host microbiome, carrier growth
rate, transformation efficiency, drug expression rate by the carrier or transformed host cells and drug
stability in the GIT. These factors may be subjected to inter- and intraindividual fluctuations as a result
of the dynamic GI environment and in turn correlate with fluctuations in efficacy.
Nucleotide formulations have been investigated as well. The investigated formulations were ASO,
siRNA, miRNA or chemical modifications thereof to increase the stability and/or efficacy. ASO are
single-stranded nucleotides that are typically 10–50 nucleotides long whereas siRNA are typically
15–25 nucleotides long. Both can modulate gene expression by a variety of mechanisms which are
out of the scope of this review. Simplified and generally speaking, ASO can bind to complementary
pre-mRNA or mRNA and alter splicing or induce degradation by endogenous RNase H, respectively,
whereas siRNA binds to endogenous RNA-induced silencing complex and thereby induces mRNA
degradation. Both approaches aim to silence target genes (reviewed in: [74,81–85]). However, miRNA
are endogenously produced small, non-coding RNA strands of typically 20–25 nucleotides long that
are implied in several cellular and gene regulation processes (reviewed in: [86,87]).
Targeted cytoplasmic nucleotide delivery is a prerequisite for gene silencing. To deliver nucleotides
to targeted cells, the formulation must protect the nucleotides from environmental degradation, aid in
targeted cellular uptake by endocytosis, and must facilitate endosomal escape of the nucleotides into
the cytoplasm [73,82,83]. These processes can be influenced by different approaches and formulation
strategies of which several are discussed in this review. However, besides targeting the drug to the site
of inflammation, these processes add jet another major challenge for drug efficacy due to the complexity
of these mechanisms. Furthermore, the released drug concentration at the site of inflammation may not
always correlate with intracellular drug concentrations. The complexity of targeted ASO is depicted
by mongersen, an orally administered ASO against Smad7 aimed to restore transforming growth
factor-beta (TGF-β) signaling. The phase II clinical trial results [88] were encouraging whereas the
phase III clinical trial showed no significant efficacy [89]. The investigators stated that no mucosal
drug concentrations were measured during the phase III trial, which may have partly explained the
observed ineffectiveness. Therefore, strategies to evaluate the effective delivered dose in animal as
well as clinical studies are of great value for oligonucleotide therapy.
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3.2. Antibodies
The efficacy of rectally administered IFX (IFX-enema) compared to IV administration was
investigated in a mouse model of acute DSS colitis [90]. As expected, IV IFX (5 mg/kg) showed a
significant effect in reducing loss of bodyweight, loss of colon length and disease activity index (DAI).
These effects were similar for 300 µg rectally administered IFX. Furthermore, histopathologic analysis
showed a marked decrease in inflammation of both treatment groups compared to control. Interestingly,
analysis of IFX in serum, colonic mucosa, and stools showed that the levels in serum and colon were
significantly lower in colitic mice compared to healthy mice in the IV treatment group. However,
IFX levels in stool were remarkably higher in colitic mice compared to healthy mice. An explanation
for this may be the loss of IFX via ulcerated epithelial surfaces in stools, resulting in the low in vivo
concentrations. This phenomenon has been reported in UC patients [91]. These results show that the
efficacy of rectally administered IFX is comparable to IV IFX in a mouse model of acute DSS colitis.
V565 is a 115 amino acid 12.6 kDa single domain antibody [92]. In vitro results showed that V565
neutralized sTNF-α and tmTNF-α with a comparable efficacy as adalimumab. In GI simulation studies,
V565 stayed active with no remarkable loss of activity after 2 h, 2 h and 16 h incubation in mouse
small intestine supernatants, human ileal fluids and human fecal extracts, respectively. Moreover,
no substantial loss of activity was observed after 6 h incubation with the digestive enzymes trypsin,
chymotrypsin and pancreatin. However, all activity was lost after 2 h incubation with pepsin. In vivo
results in healthy mice confirmed these observations since active V565 could be measured in the
stomach, small intestine, caecum and colon during GI transit. In a DSS colitis model, V565 could
penetrate the colonic mucosa and submucosa whereas no noticeable penetration in healthy colons was
observed, which indicates that orally administered antibodies are able to penetrate the inflamed regions
in vivo. Interestingly, serum levels of V565 could be detected in colitic mice, but not in healthy mice.
In addition, colon concentrations correlated with serum concentration in colitis mice. These results
indicate that V565 could be absorbed during colitis, presumable by the enhanced permeability and
retention effect of the inflamed colon [93]. Though no in vivo effectiveness study was performed,
ex vivo experiments with human IBD tissue showed that V565 could inhibit the phosphorylation of
several signaling proteins implied in the proinflammatory response.
The same research group [94] investigated V565 formulated in a tablet coated with the pH-sensitive
polymer Eudragit L100 (pH-threshold ≥6) [95]. This coating was applied for the time-dependent drug
release in the ileum, cecum, colon and rectum. Dissolution experiments showed that V565 was released
in a sustained manner after 2 h at pH ≥ 6. In vivo experiments in cynomolgus monkeys showed that
the formulation disintegrated in the small intestine and reached parts of the lower colon. However,
GI transit time and pH values of these monkeys [96,97] may not be representative of those seen in
humans [98–103]. Measured fecal concentrations indicated that V565 transited through the GIT after
the coating disintegrated. Serum concentrations of V565 were also observed in this study, showing that
V565 is partly absorbed after oral administration. V565 has been investigated in a clinical study [104]
and is discussed in Section 4.
AVX-470 is an orally administered antibody against TNF-α derived from the colostrum of cows
that have been immunized with TNF-α [105]. The in vitro potency of AVX-470 is comparable to
IFX. In a prophylactic acute DSS and TNBS colitis model, mice were given AVX-470 in doses of
1–10 mg/day before the induction of colitis. Endoscopy scores in both colitis models showed significant
improvement with a trend towards a dose-dependent relationship. Furthermore, the efficacy was
comparable with prednisolone or etanercept [106] in a chronic colitis model. In this model, TNF-α
and proinflammatory cytokines mRNA were significantly reduced (~50%). These findings were
mirrored by histopathologic experiments, which showed that AX-470 penetrated predominantly in
the lamina propria, mucosa and muscularis mucosa region of inflamed, but not healthy colon of mice.
As with V565, this observation show that orally administered antibodies penetrate the inflamed sites
of the colon in vivo [94]. However, systemic exposure after oral treatment was low to non-existing,
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demonstrating the site-specific effect of this formulation. AVX-470 has been investigated in a clinical
study [107,108] and is discussed in Section 4.
Avian-anti-TNF-α is an oral formulation containing polyclonal anti-TNF-α antibodies derived
from the yolks of immunized hens [109]. An in vitro experiment confirmed the TNF-α neutralizing
potency of the antibody. Moreover, significant effects on colon weight, myeloperoxidase (MPO)
activity, histopathology scores and colon morphology scores were seen in an acute TNBS colitis
model in rats after oral treatment with 600 mg/kg/day. In this same colitis model, Avian-anti-TNF-α
was compared with oral sulfasalazine (200 and 1000 mg/kg/day) or dexamethasone (2 mg/kg/day).
The efficacy of Avian-anti-TNF-α was comparable with these treatment groups. The efficacy was
further investigated in a chronic colitis model and these results also showed significant effects on colon
weight, histopathology scores and colon morphology scores, though no comparison with other drugs
was investigated in the chronic colitis model. Histological analysis showed that Avian-anti-TNF-α
could be detected in the lamina propria, muscularis mucosa and submucosa of ulcerated sites of the
colon, further emphasizing that orally administered antibodies are able to penetrate the inflamed
colonic regions in vivo [94,105].
3.3. Antisense Oligonucleotides
ISIS 25302 is an ASO targeting murine TNF-α. In the first animal study investigating the efficacy
of SC doses ranging from 0.25–12.5 mg/kg, a dose-dependent decrease in disease severity and colonic
TNF-α mRNA expression was reported [110]. Another animal study in db/db mice, known for the
expression of TNF-α in their adipose tissue [111], showed a significant reduction of TNF-α mRNA (64%)
expression after IPadministration [112]. Furthermore, in an acute DSS colitis model significant effects
on colon length and DAI was observed after multiple IV dose of 1 mg/kg. These effects were comparable
with mice treated with 25 µg anti-TNF-α antibody. A trend towards a linear dose–effect correlation was
observed in a chronic colitis model with doses ranging from SC 0.25–12.5 mg/kg, showing significant
effects on DAI, histopathology scores and colonic TNF-α mRNA levels. These results were comparable
with 15 µg anti-TNF-α antibody. In another chronic colitis model of IL-10−/− mice investigating
prophylactic as well as therapeutic treatment regimens with SC doses ranging from 0.01–10 mg/kg,
reductions in histopathology scores and TNF-α as well as interferon-gamma (IFN-γ) levels measured
in colonic organ cultures were seen. Since ISIS 25302 was administered systemically in these studies,
off-target, systemic anti-inflammatory effects contributing to the favorable response cannot be ruled
out [110,112].
In a follow up study, ISIS 25302 was associated with galactosylated low molecular
weight chitosan (Gal–LMWC–ASO) to form a nano-complex [113]. The galactose residues of
Gal-LMWC have high affinity for macrophage galactose-type lectin (MGL), which is expressed on
macrophages. MGL expression is enhanced during immune activation and facilitates receptor-mediated
endocytosis [114]. In vitro results indeed showed a substantial increase in macrophagic transfection of
Gal–LMWC–ASO compared with naked ISIS 25302. Furthermore, intracolonic administration of 5 mg
ASO/kg showed that Gal–LMWC–ASO accumulated in the inflamed colon of mice with no remarkable
accumulation in other organs. Interestingly, Gal–LMWC–ASO did not accumulate in healthy colon of
mice, indicating that nucleotides penetrated into colonic tissue and targeted activated macrophages.
In two colitis models, 5 mg/kg intracolonic administered Gal–LMWC–ASO significantly reduced
colonic TNF-α mRNA and protein levels. This effect was more prominent compared to naked ISIS
25302. For instance, Gal–LMWC–ASO reduced TNF-α mRNA and protein levels by approximately
60–90% and 50%, respectively, whereas the reduction seen with ISIS 25302 alone was approximately 50%
and 10%, respectively. A similar reduction of inflammatory Th1 and Th17 cytokines was observed and
this effect was also more prominent for Gal–LMWC–ASO compared to naked ISIS 25302. These results
were mirrored by several disease parameters such as mortality, body weight and colonic MPO activity.
Another formulation using ISIS 25302 is GGG-ASO. However, GGG-ASO is a microspheric oral
formulation (~650 µm) in which ISIS 25302 is complexed in a glucomannan–gellan gum mixture.
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Due to this polysaccharide mixture, the formulation has a time-dependent release mechanism targeting
the colon. Furthermore, the mannose entities of glucomannan aid in macrophagic phagocytosis of
the formulation, which express mannose receptors [115]. In vitro as well as in vivo results indeed
showed that the mannose receptor was highly expressed on macrophages, but not colonic epithelial
cells and that the formulation therefore was predominantly targeted to colonic macrophages. In colitic
mice, oral administration of 50 mg/kg GGG-ASO significantly decreased colonic TNF-α expression by
50%. Significant reductions in other colonic cytokines were observed as well. Additionally, significant
effects on mortality, loss of body weight, DAI, colon length, MPO activity, and histological scores
were reported.
CAL-ASO is also a formulation using ISIS 25302, which is complexed with lentinan and
encapsulated in a chitosan–alginate hydrogel [116]. The complexion with lentinan protects the
ASO from degradation while the chitosan–alginate hydrogel yields an oral colon-targeted formulation.
In vitro experiments also demonstrated that lentinan increased macrophagic uptake of the formulation
and this resulted in reduced TNF-α mRNA and protein expression by 50% and 40%, respectively.
Furthermore, in vivo tissue analysis as well as imaging showed that the formulation was targeted to the
small intestine and colon. Colonic TNF-α secretion was significantly reduced by 30% and significant
effects on loss of body weight, colon length, spleen size, MPO activity, and colonic malondialdehyde
(MDA) levels were also observed.
SPG-ASO is an enema containing ASO against TNF-α complexed with the polysaccharide
schizophyllan, which is a β-(1–3) glucan [117]. The complexion resulted in a stable ASO formulation
that was targeted to cells expressing the Dectin-1 receptor. This pattern recognition receptor is expressed
on immune cells and can interact with β-(1–3) glucans to aid in phagocytosis [118]. It was shown that
Dectin-1 was significantly upregulated during DSS colitis in mice. Furthermore, SPG-ASO uptake by
cells expressing Dectin-1 was significantly increased compared to ASO alone. Rectal administration of
0.2 mg/kg SPG-ASO resulted in significant improvements on body weight, colon length and endoscopic
evaluation. Moreover, the expression of TNF-α, IL-1β and IL-6 mRNA was significantly inhibited
(~80%) and this effect was the strongest for the SPG-ASO when compared to the rectal administration
of the ASO alone.
ASO-miR-301a is an enema containing an ASO against miRNA 301a (miR-301a) [119], which is
involved in the pathogenesis of several autoimmune diseases and cancers [120]. Levels of miR-301a
were increased in the inflamed mucosa and peripheral blood mononuclear cell of CD and UC patients
whereas no increased levels were observed in the unaffected mucosa of these patients. Furthermore,
TNF-α expression in CD patients was positively correlated with miR-301a expression in the intestinal
mucosa [119,121]. Intracolonic administration of ASO-miR-301a in a TNBS acute colitis model in mice
resulted in a significant inhibition of miR-301a expression. This was mirrored by a significant inhibition
of TNF-α, IL-17A and RAR-related orphan receptor gamma-t (RORγt) expression—all of which were
inhibited by approximately 50%. Additionally, the formulation significantly alleviated colitis symptoms
as assessed by DAI, colon length, loss of body weight and histological scores. Phenotype analysis of T
cells showed that these anti-inflammatory effects were predominately the result of Th17 cell inhibition.
Though the formulation inhibited TNF-α levels locally in the colon, other effects resulting from the
interference with different pathways in different tissues cannot be ruled out for miR-301a has different
effects in different tissues [120].
3.4. microRNA
Gal-LMWC-pre-miR-16 is a formulation containing miR-16 precursor complexed with
galactosylated low molecular weight chitosan in view of macrophagic targeting by the MGL [122].
Studies have reported the involvement of miR-16 in IBD and this formulation was therefore
investigated [123–125]. Intracolonic administration of the formulation corresponding to 5 mg/kg
miR-16 targeted TNF-α and IL-12p40 production. The latter is a subunit of the proinflammatory
cytokines IL-12 (IL-12p70) and IL-23 and are both involved in IBD [126]. In a TNBS colitis model,
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the formulation was predominately targeted to colonic macrophages and miR-16 precursor was
subsequently metabolized to miR-16. Significant reductions in TNF-α and IL-12p40 mRNA (~50%) as
well as protein (~50%) levels were reported. These observations were consistent with the reported
significant effects on mortality and disease severity. Comparable anti-inflammatory results in an acute
TNBS model have been reported with miR-195, a miRNA also implicated in IBD [127]. However,
the latter study did not report a route of administration. Crucially, the authors used a TNBS colitis
model for the investigation of UC. To the best of our knowledge, it is uncommon to use this animal
model for UC research since the DSS colitis model correlates better with UC [79,80,128].
Of note, the observed anti-inflammatory effects of the investigated miRNA’s may have been partly
the result of the miRNA’s interfering with other targets than TNF-α and IL-12p40 expression since
both are expressed and regulated in a wide variety of cells [123,125,127,129].
3.5. Small Interfering RNA
PACC-siRNA-TACE is an IV formulation consisting of siRNA against TACE complexed in
disulfide-linked poly arginine–cysteine complex (PACC) [130]. This biodegradable complex envelops
the siRNA, which protects, stabilizes and facilitate targeted cellular uptake. In vitro results showed
that PACC significantly increased macrophagic uptake and decreased TACE mRNA levels and TNF-α
production compared to siRNA-TACE alone. TNF-α production was inhibited in a dose-dependent
manner up to 50%. In an acute colitis mode, IV administration of a dose corresponding to 20 µg siRNA
showed that TACE expression was inhibited, resulting in significant reductions of TNF-α (~75%), IL-1β
(~75%) and IL-6 (~50%) production. Consistent with these observations were significant reductions
in mortality and disease severity as well as effects on the expression of several proteins involved in
inflammatory processes. In addition, comparable effects were observed in a chronic colitis model.
Taken together, these results show that targeting TACE results in the in vivo inhibition of acute and
chronic inflammatory processes. However, this formulation was administered IV and the observed
effects may have been partly the result of systemic immune suppression as opposed to localized effects
in the colon.
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Table 1. Summary of the animal studies investigating the local effects of anti-TNF-α therapy. Abbreviations: AAT—alpha 1-antitrypsin; ASO—antisense
oligeonucleotide; DAI—disease activity index; DSS—dextran sodium sulfate; Fab’—antigen-binding fragment; Fc—fragment crystallizable region;
GM-CSF—granulocyte-macrophage colony-stimulating factor; H&E—hematoxylin and eosin; IC—intracolonic administration; ICH—immunohistochemistry;
IFN-γ—interferon-gamma; IFX—infliximab; Ig—immunoglobulin; IκB-α—nuclear factor of Kappa light polypeptide gene enhancer in b-cells inhibitor-alpha;
IP—intraperitoneal injection; IV—intravenously administered; Ly6 g—lymphocyte antigen 6 complex; MCP-1—monocyte chemoattractant protein 1;
MIP-1α—macrophage inflammatory protein 1-alpha; MDA—colonic malondialdehyde content; miR—microRNA; MPO—myeloperoxidase activity assay;
NADPH—nicotinamide adenine dinucleotide phosphate oxidase activity; NS—not stated; PLGA—poly(lactic–co-glycolic acid); PO—orally administered, per os;
pSer32/Ser36—phosphorylated serine-32/serine-36; Rec.—rectally administered; ROA—route of administration; ROS—reactive oxygen species; SC—subcutaneous
injection; siRNA—small interfering RNA; TACE—tumor necrosis factor-α-converting enzyme; TNBS—trinitrobenzenesulfonic acid; TGF-β—transforming growth
factor-beta; TNF-α—tumor necrosis factor-α; scFv—single-chain variable fragment; sTNFR2—soluble TNF receptor 2.
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GTC-siRNA is an intracolonic administered formulation consisting of nanoparticles that
contain siRNA against TNF-α complexed with galactosylated trimethyl chitosan–cysteine [133].
In macrophages, GTC-siRNA uptake was significantly increased compared to naked siRNA showing
that galactosylated trimethyl chitosan–cysteine aids in cellular targeting. Significant in vivo anti-colitic
effects on colonic TNF-α mRNA and protein expression, loss of body weight, MPO activity and
histology were observed. Noteworthy, experiments on formulation particle size and binding affinity of
siRNA for galactosylated trimethyl chitosan–cysteine showed that in vitro macrophagic endocytosis
was not dependent on particle size (range 175–450 nm). However, cytoplasmic internalization of
siRNA, in vitro epithelial permeability, and in vivo efficacy was dependent on these factors. In general,
a formulation with a greater particle size (450 nm) and moderate binding affinity for the siRNA was
the most efficacious. Due to the size, these particles were better retained in the colonic lumen whereas
the moderate binding affinity assures that the siRNA remains complexed, and therefore, protected
from the harsh GI environment while facilitating intracellular release as opposed to a stronger binding
affinity. These observations may therefore give guidance in the development of nucleotide formulations
intended for the treatment of IBD.
Lipoplex-siRNA-2 is an enema containing liposomal, chemically modified siRNA against
TNF-α [135]. Chemically modifying siRNA may increase the silencing capacity, resistance to
degradation or both. For instance, a propanediol and double methylation of siRNA at the 3′-
and 5′-end, respectively, showed an increased silencing capacity and stability. This siRNA was
then formulated to a liposomal enema and administered to colitic mice. Significant reductions in
colonic mRNA expression (~40%) as well as mortality, DAI, MPO activity and histological scores
were observed. In addition, gene analyses of 25,000 genes showed that 4000 genes were significantly
altered after colitis induction. Of these 4000 genes, expression of 60 were significantly altered during
Lipoplex-siRNA-2 treatment showing the involvement of TNF-α in a wide range of proinflammatory
processes. Comparable effects on TNF-α inhibition and histology has been reported in an earlier study
that also investigated an enema containing liposomal siRNA against TNF-α (Lipoplex-siRNA-1) [134].
CycD-siRNA is an enema containing nanoparticles (~240 nm) consisting of siRNA against TNF-α
complexed with amphiphilic cyclodextrin [136]. This complexion yields a stable siRNA formulation
with good transfection properties [149]. In simulated colonic fluids mimicking fasted and fed state,
CycD-siRNA remained stable for up to 24 h. In vitro results showed significant inhibition of TNF-α
expression of up to 80%. The effectiveness was investigated in an acute DSS colitis model in mice.
These in vivo results showed remarkable improvements in disease severity. Interestingly, TNF-α
and IL-6 expression in the proximal colon was significantly reduced whereas IL-6 expression in the
distal colon was and TNF-α expression was not significantly inhibited. It has been shown that TNF-α
expression in the proximal colon is higher compared to the distal colon in DSS-induced colitis in
mice [150]. This may, partly, explain the higher level of gene silencing in the proximal colon, as brought
for by the authors [136].
CaP-siRNA is an enema containing nanoparticles (~150 nm) of siRNA against TNF-α loaded
on calcium phosphate, which is then encapsulated in poly(lactic–co-glycolic acid) (PLGA) coated
with polyethyleneimine (Figure 3) [137]. Calcium phosphate was used as an siRNA carrier, whereas
the PLGA–PEI encapsulation served as a protection mechanism against degradation that targeted
and released the siRNA in a controlled manner [151–154]. The formulation showed a significant
reduction in TNF-α expression in vitro. Rectal treatment of colitic mice with 12 µg showed a significant
downregulation of colonic TNF-α (~50%), also showing significant effects on loss of body weight, DAI,
hematocrit levels and histology scores. Further analyses showed that cellular uptake in the distal colon
was the greatest and this uptake was enhanced during colitis, which also shows that the nucleotides
could penetrate into colitic tissue [113]. The cells predominantly targeted by CaP-siRNA were colonic
dendritic cells, macrophages and T cells, whereas colonic B cells showed minimal uptake.
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US-siRNA is an enema containing siRNA against TNF-α which is administered concurrently
with rectal 40-kHz ultrasound bursts [138]. Ultrasound can reversibly increase tissue and cellular
membrane permeability by a mechanism known as transient cavitation, which facilitates the delivery
of oligonucleotides [155–157]. Short bursts of 40-kHz ultrasound administered by a rectal probe were
safe and well tolerated by colitic mice. Rectal administration of 200 ng of US-siRNA combined with
0.5-s bursts of 40-kHz ultrasound resulted in a significant alleviation of colitis as assessed by fecal and
histopathology scores. Proximal as well as distal colonic TNF-α levels were significantly lower (~80%)
compared to rectally administered siRNA without ultrasound. Interestingly, ultrasound could also
mediate colonic mRNA delivery, which is a bigger macromolecule compared to the mentioned siRNA
against TNF-α (950 kDa vs 16 kDa, respectively). Therefore, this method could serve as an approach
for the delivery of different nucleotide formulations.
ROS-siRNA is an oral formulation consisting of nanoparticles (~600 nm) containing siRNA against
TNF-α encapsulated in a reactive oxygen species (ROS)-sensitive material [139]. The ROS-sensitive
encapsulation ensures that the orally administered siRNA is protected against the harsh GI environment,
but is released at sites of GI inflammation where ROS concentrations are high [158,159]. For instance,
biodistribution analyses showed that colons, but not other tissues of colitic mice had an increased uptake
of siRNA compared to healthy mice. Additionally, the tissue-targeting performance of ROS-siRNA was
superior compared to a formulation that used a β-glucan encapsulation, which is a suitable method
for oral siRNA delivery [160]. Multiple daily doses of ROS-siRNA corresponding to 0.23 mg/kg/day
siRNA showed significant improvements in loss of body weight and histology as well as re uctions
in colonic TNF-α, IL-1, IL-6, IL-12 and INF-γ expression. Together these experiments showed that
ROS-siRNA is not only targeted to the colon, but to the inflamed sites of colitic mice. This platform
may therefore be used to develop novel therapies targeting the inflamed tissues in IBD.
GalC-siRNA is an oral formulation consisting of nanoparticles (~250 nm) containing siRNA against
TNF-α loaded on PLGA after which a galactosylated chitosan layer is added for macrophagic targeting
by MGL [140]. In vitro studies showed that the formulation had controlled-release characteristics
and was able to protect siRNA against enzymatic degradation in GI homogenates of mice. Moreover,
galactosylated chitosan layer indeed increased cellular uptake by macrophages compared to a
formulation without galactose modifications. In colitic mice, the formulation significantly reduced
TNF-α mRNA (50%) and protein (45%) expression and ameliorated colitis symptoms reflected by the
DAI, loss of body weight, colon length, MPO activity and histopathology. Three oral doses ranging
from 66–660 µg/kg were administered, but no clear dose–effect relationship was observed.
Nanoparticle-in-microsphere oral delivery system (NiMOS) is also an oral formulation containing
nanoparticles (~210 nm) entrapped in microspheres (~3 µm). This system can be used to encapsulate
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siRNA against TNF-α (NiMOS-siRNA) [141]. After oral administration it remains stable in gastric
conditions but releases the content at intestinal pH in the presence of lipases. The effectiveness of
this formulation has been investigated in in vivo experiments. These results showed a significant
reduction in colonic TNF-α mRNA (60%) and protein (80%) levels in colitic mice treated with 1.2 mg/kg.
Expression of several colonic proinflammatory cytokines and chemokines were reduced as well and
this resulted in significant clinical effects as assessed by loss of body weight, colon length, MPO activity
and histological evaluation. Additionally, the same research group [144] has investigated NiMOS
containing a combination of siRNA against cyclin D1 (CyD1) and TNF-α (NiMOS-siRNA-CyD1). CyD1
is a protein involved in cell proliferation [161] and is overexpressed in IBD [162,163]. Similar effects with
regards to TNF-α, cytokines, chemokines, histopathology and clinical improvements were observed
whether the formulation contained siRNA against only TNF-α or CyD1—or a combination thereof
given as a 1.2-mg/kg oral dose. Interestingly enough, the most pronounced effects were seen with the
formulation containing only siRNA against CyD1, indicating that CyD1 is involved in key inflammatory
processes in IBD.
CA-siRNA is an oral colon-targeted formulation containing nanocomplexes of siRNA against
TNF-α encapsulated in chitosan–alginate [142]. This formulation released the nanocomplex in the
intestinal environment at a pH 5-6. In an acute inflammation model, mice were first pre-treated orally
with 5 mg of the formulation. Subsequently, LPS was administered systemically to induce an acute
inflammatory state. Thereafter, TNF-α levels in blood, liver and colon were analyzed. CA-siRNA
treatment significantly reduced TNF-α levels in the blood and colon, but not the liver. TNF-α levels in
the blood and colon were reduced by 16% and 94%, respectively, demonstrating the effectiveness as
well as targeting performance of this formulation.
To increase the targeting performance, the same research group synthesized CA-Fab’-siRNA [143].
This formulation is a nanoparticle containing siRNA against TNF-α enveloped by a surface bearing a
covalently bonded antigen-binding fragment (Fab’) of the F4/80 antibody which is further encapsulated
in a chitosan–alginate hydrogel for colonic targeting. The F4/80 antibody specifically targets murine
macrophages [164]. Figure 4 shows this formulation without the chitosan–alginate hydrogel.
This approach was used to target the oral formulation to the colon after which the Fab’ portion
specifically interacts with the colonic macrophages, inducing endocytosis and TNF-α mRNA silencing.
Several cytotoxicity tests showed that the formulation was biocompatible. Furthermore, in vitro results
showed that the formulation preferentially interacted with cells expressing the F4/80 protein and
that macrophage endocytosis was increased compared with a formulation without the Fab’ portion.
In addition, the formulation significantly reduced the in vitro TNF-α secretion by activated macrophage
and the in vivo efficacy in mice was confirmed by substantial reductions in loss of bodyweight, MPO
activity and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκb)
pathway as assed by nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha
(IκB-α) protein analysis.
Gal-siRNA-IL-22 is an oral formulation as well and consist of nanoparticles containing the
cytokine IL-22 and siRNA against TNF-α in galactosylated PLGA, which is further encapsulated in
a chitosan–alginate hydrogel [145]. A combination of IL-22 and siRNA against TNF-α was chosen
based on data that show that IL-22 possesses mucosal-healing properties [165]. The nanoparticle
without the chitosan–alginate encapsulation was ~260 nm and in vitro results showed that macrophagic
uptake of the nanoparticle was significantly greater compared to a non-galactosylated formulation.
In vitro TNF-α inhibition confirmed these results, showing a significantly increased inhibition of the
galactosylated formulation. In vivo biodistribution experiments showed that the formulation was
targeted to the colon and that siRNA penetration was the greatest in the mucosa of colitic mice compared
to healthy mice, which further shows that nucleotide penetration into colonic tissue is feasible [113,137].
Oral treatment of colitic mice with Gal-siRNA-IL-22 corresponding with 20 µg/kg siRNA and 50 µg/kg
IL-22 showed significant improvements in disease severity as assessed by loss of body weight, colon
length, spleen weight, histology and MPO activity. Interestingly, colonic TNF-α mRNA expression of
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colitic mice treated Gal-siRNA-IL-22 did not differ significantly compared to healthy control whereas
an increase was seen for mice treated with the same formulation that contained only IL-22 or siRNA
against TNF-α. This increased efficacy of the combination therapy was consistent with the other
investigated disease parameters, which suggests that a combination of anti- and proinflammatory
therapy is superior to either one.
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3.6. Prokaryotes
Lacto-scFv is the prokaryote Lactococcus lactis, subspecies cremoris MG1363, carrying an eukaryotic
expression plasmid coding for a single-chain fragment variable (scFv) antibody against TNF-α in view
of transforming the epithelial cells of the host [146]. This prokaryote is extensively studied, apathogenic
and non-invasive [166]. In an acute colitis model in mice, oral treatment with once daily 2.0–2.5 × 109
colony-forming units (CFU) giving for four days resulted in significant effects on DAI, loss of body
weight, colon length, histological scores and CRP. Furthermore, significant downregulation of colonic
mRNA expression of TNF-α (~50%) and proinflammatory cytokines was observed. No adverse
effects were reported. Taken together, these observations show that Lacto-scFv was able to deliver the
eukaryotic plasmid for expression in the host’s cells of the GIT, and thereby, ameliorated colitis in vivo.
In another study investigating the anti-inflammatory effects of engineered L. lactis, the exact
same strain was modified to secrete bivalent single domain antibody fragments (nanobody) against
TNF-α (Lacto-Nanobody) [147]. This nanobody could neutralize sTNF-α as well as tmTNF-α.
Oral administration of multiple doses of 2 × 109 CFU resulted in an average of 4 × 108 CFU in the entire
colon of colitic mice producing approximately 10 ng nanobody per entire colon. These nanobodies
were detected in the mucosa and lamina propria while no nanobodies could be detected in the systemic
circulation. Positive effects on histopathologic scores and MPO activity was seen in two chronic colitis
models. However, TNF-α, cytokines, inflammatory markers or clinical scores were not analyzed and
therefore the effects of this formulation on chronic inflammatory processes is unclear.
3.7. Eukaryotes
PRX-106 is an oral formulation containing plant–cell-expressed (BY-2 cell line) recombinant fusion
protein of sTNFR2 fused to the Fc part of human immunoglobulin (Ig)G1. The DNA sequence of this
protein expressed by the plant cell line is the same as for the commercially available etanercept [148].
In vitro stability studies showed that the protein remained stable during simulated gastric conditions at
different pH values. This effect was attributed to the protective effect of the plant cell wall protecting the
expressed PRX-106 from the harsh simulated GI environment. In a TNBS acute colitis model, PRX-106
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had a significant effect on loss of body weight and improved the histopathology. No colonic levels of
TNF-α or cytokines were analyzed and therefore, the local in vivo anti-inflammatory effects of this
formulation in this animal model remains unclear. However, this formulation has been investigated in
a clinical trial [167] and is discussed in Section 4.
4. Clinical Studies on Local TNF-α Inhibition
4.1. Considerations
The studies that investigated local TNF-α inhibition in humans were mostly limited and small
pilot studies (Table 2). Furthermore, several of these studies were inherently selection biased since
patients were included for unconventional therapy due to disease activity that could not be resolved
with conventional therapy. In some studies, local therapy was accompanied with surgery, another
form of intervention, and/or without a control group. Moreover, the disease type and investigated dose
differed as well as the definition of ‘effectiveness’. We therefore chose ‘a favorable clinically relevant
response’ as our definition of ‘response’. Due to these limitations, no unambiguous statements about
the efficacy regarding local TNF-α inhibition in IBD can be made. However, these data may provide
insight into whether local TNF-α inhibition in IBD is feasible, induces a clinically relevant response,
and to some extent the mechanism of action of anti-TNF-α therapy in IBD. Of note, research shows
an interplay between systemic anti-TNF-α therapy and a favorable response related to the effects
on the microbiome [66–69,168]. Currently it is unclear whether local TNF-α inhibition at the site of
inflammation induces these same effects to the same extent. Local TNF-α inhibition generally results
in higher drug concentration at the site of inflammation, which is predominantly the gut. This could
potentially result in a more prominent effect on the locally present microbes. On the other hand,
systemic administration of anti-TNF-α therapy exposes the patient systemically to TNF-α inhibition,
and therefore, the overall effect on the microbiome may be more prominent. It would therefore be
interesting and valuable to investigate the changes and responses of the microbiome to local TNF-α
inhibition compared to systemically administered anti-TNF-α therapies.
4.2. Local Injections
In the first study investigating local anti-TNF-α administration in perianal fistulizing CD, a dose
of 20 mg IFX divided by several SC injections was administered at the site of inflammation in 9
patients. This study included patients that did not have a sustained response to IV IFX or other
systemic drugs. A clinical response was seen in 7 patients of which 4 showed complete healing of the
fistulas in 4 weeks. During the 6-month follow-up period no development of ADA was observed [169].
In another study of perianal fistulizing CD investigating 20-mg local IFX injections, 11 patients were
included with long-existing luminal disease complicated by perianal disease manifestation. These
patients did not respond to conventional treatment such as mesalamine, cortisone, and/or azathioprine.
A favorable response was seen in 8/11 patients who received 3–5 injections during an average follow-up
of 10.5 months [170]. Similar results with approximately the same doses of local injections at the
site of inflammation in perianal fistulizing disease have been reported in two other studies. In these
pilot studies [171,172] patients were included who did not respond to or had a contraindication to IV
IFX. Furthermore, patient refractory to conventional therapy were included as well. Approximately
60% of the included patient responded to local IFX therapy (range: 2–12 injections). Clinical healing
or complete fistula closure was reported in some patients during a follow-up period ranging from
7–43 months. However, one patient was switched to IV IFX after no favorably response was seen
during local treatment and developed a delayed hypersensitivity reaction, presumed by the authors as
a consequence of local IFX therapy [172]. No major adverse events were reported in the other studies
investigating local IFX injections in perianal fistulizing CD [169–171].
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Table 2. Summary of the clinical studies investigating local TNF-α inhibition. Abbreviations: ADA—anti-drug antibodies; IFX—infliximab; NA—not applicable;
NS—not stated; PK—pharmacokinetic; PO—orally administered, per os.
Disease Drug ROA Dosage Therapy Follow-up Response a Remarks Reference
CD, perianal
fistulas (n = 9) IFX
Local
injection 20 mg 0, 1, 3 weeks 6 months 78%
ADA did not develop during
follow-up [169]
CD, perianal
fistulas (n = 15) IFX
Local
injection 15–21 mg




Combined with surgical treatment;
included nonresponders to IV IFX











Including patients not responding
to conventional systemic therapy [170]
CD, perianal







Combined with surgical treatment;
included nonresponders to IV IFX [172]
CD, perianal
fistulas (n = 16) adalimumab
Local




Combined with surgical treatment
and including patient who did not
respond to local IFX therapy
[173]
CD, perianal
fistulas (n = 33) adalimumab
Local
injection 40 mg Every 15 days
11 (7–14)
months c 40% Combined with surgical treatment [174]
CD, perianal
fistulas (n = 12) adalimumab
Local
injection 20 mg Every 2 weeks
17.5 (5–30)
months b 100% Including surgical therapy [175]
CD, perianal
fistulas (n = 9) adalimumab
Local
injection 10 mg Every 2 weeks NS 100%
Investigated different T cell










localized regions of <5 cm [177]
CD, isolated
symptomatic
regions (n = 4)




strictures (n = 3) IFX
Local
injection 90–120 mg variable 5–8 months 100% Manual dilation in 1 patient [179]
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Table 2. Cont.
Disease Drug ROA Dosage Therapy Follow-up Response a Remarks Reference
CD, rectal stenosis
(n = 2) IFX
Local
injection 25 mg variable NS 100% Combined with balloon dilation [180]
CD, small bowel
strictures (n = 6) IFX
Local
injection 40 mg 0, 2, 6 weeks 6 months 100% Combined with balloon dilation [181]
UC, refractory
proctitis (n = 1) IFX Enema 100 mg 6 days NS 100%
Patient with subtotal colectomy
and ileorectal anastomosis [182]
Healthy volunteers
(n = 14) PRX-106 PO 2–16 mg 5 days 10 days NA
PRX-106 was not systemically







capsule PO 0.2–3.5 g 4 weeks 7 weeks 14%
d Colonic biopsies were analyzed in
a separate study [107] [108]




555–1665 mg Single dose
No follow-up NA
PK study
[104]UC (n = 5) 1110 mg 7 days Tissue penetration study
Non–CD Ileostomy
(n = 4) 1665 mg Single dose Ileal fluid recovery study
a—specifies ‘a favorable clinically relevant response’; b—mean (range); c—median (range); d—as assessed by clinical remission, endoscopic response and endoscopic remission vs. 0% for
the placebo group.
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Local adalimumab injections combined with surgical therapy has also been investigated in perianal
fistulizing CD. One study investigating 40-mg injections every 15 days reported complete closure of
fistulas in 40% of patients (n = 33) after a median number of 9 injections and median follow-up of 11
months. These patients responded without the need for other medical therapy. However, 24% failed to
respond to therapy and one adverse event (complication not stated) was reported [174]. Another study
reported a response of 100% in 12 patients of which 75% achieved complete cessation of fistula drainage
while the remaining patients showed only improvements [175]. The median number of injections for
each patient was 7 (range: 4–16) with an average follow-up of 17.5 months. No relapse or adverse
events were reported. Similar results with 10-mg local adalimumab injections has been reported
elsewhere, showing a response of 100% (n = 9) of which resolution of the fistula was observed in 78%
of patients after an average therapy period of 23 week [176]. Interestingly, one study investigated
the efficacy of local adalimumab injections in perianal fistulizing CD patients that showed no clinical
response to local IFX injections. The authors stated that healing of the fistulas was seen in some patients,
but did not report definitive success/failure rates nor follow-up periods [173]. A systematic review
which included six of the discussed studies [169–172,174,175] regarding local anti-TNF-α therapy
in perianal CD disease reported a partial or complete response rate of 40–100% out of 92 patients
included [183].
Endoscopy-guided local IFX injections in CD has been investigated as well. A study with 8
patients investigated the feasibility and effectiveness of IFX injected locally during colonoscopy in
localized inflamed regions (<5 cm) [177]. The dose and therapy duration varied, since this depended
on the number of inflamed regions as well as the number of colonoscopies. In general, 20–60 mg IFX
was administered per colonoscopy, which were several weeks apart (2–4 weeks) with a maximum of
three colonoscopies. These patients were concurrently treated with conventional medication and did
not relapse (follow-up range: 14–21 months). Although the endoscopy score improved in only 3/8
patients, the number and extent of the inflamed lesions were reduced in 7/8 patients. In another report
(n = 4) [178] investigating endoscopy-guided IFX injections (20–30 mg) in isolated mucosal lesions,
1 patients showed complete resolution, 2 showed partial improvement and no effect was seen in the
last patient. Therapy was variable and ranged from one local injection in total to several injections that
were weeks apart. No adverse events were reported in these two studies [177,178].
The effectiveness and feasibility of locally injected IFX in structuring CD has also been reported.
One case series (n = 3) investigated locally injected IFX (90–120 mg) in colonic strictures [179].
One patient did not respond to chronic IFX infusions, but complete resolution of the stricture was
observed after the first local IFX injection. The patient needed a total of two local IFX injections and
was symptom free during a follow-up of 5 months. Local IFX injections were effective in the other
two patients. However, one patient needed additional manual stricture dilation whereas the other
patient needed a total of 5 local injections every 4 months. The patients were followed for 5–8 months
and were symptom free during this period. In small bowel strictures of CD, a dose of 40 mg locally
injected into the strictures combined with balloon dilation at t = 0, t = 2 and t = 4 weeks showed a
response of 100% in 6 patients. No adverse events or relapses were reported during a follow-up period
of 6 months [181]. In addition, balloon dilation combined with locally injected IFX (25 mg) showed
clinical improvements in anal stenoses of CD (n = 2) [180]. However, one patient needed a total 16
injections in a period of approximately 6 years.
4.3. Topical Treatment
In our search we found that topical anti-TNF-α therapy has only been investigated in one
case report regarding a UC patient [182]. The patient suffered from refractory pancolitis not
responding to conventional therapy. Therefore, subtotal colectomy and ileorectal anastomosis took
place. Despite conventional therapy including IV IFX, severe symptoms remained. Symptoms
improved after instillation of daily 100-mg IFX enemas for 6 days. Clinical and histological scores
improved without any reported adverse events.
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4.4. Oral Therapy
PRX-106 is an oral formulation containing plant–cell-expressed (BY-2 cell line) recombinant fusion
protein of soluble TNF receptor 2 (sTNFR2) fused to the fragment crystallizable region (Fc) part of
human IgG1. This formulation is also discussed in Section 3. [148]. A phase I clinical study [167]
in 14 healthy volunteers investigated daily oral doses corresponding with 2 mg, 8 mg and 16 mg
of active compound for 5 days. Analyses of different T cell subtypes showed minimal inhibitory
or stimulatory effects on the differentiation of these cell types. In general, no remarkable effects on
TNF-α, IFN-γ IL-4, IL-10 and IL-12 were observed. Additionally, no clear dose–response effect was
reported. The treatment-related adverse events were mild. To date, it is unclear whether this specific
formulation has an anti-inflammatory effect or is efficacious in the treatment of IBD patients. However,
IBD treatment with SC etanercept is not efficacious in active CD [184].
AVX-470 is an orally administered antibody against TNF-α and is also discussed in Section 3. [105].
The efficacy and safety in active UC patients has been investigated in a double-blind, placebo-controlled
dose-finding study [107,108]. Patients (n = 37) with an established diagnosis of UC with colonic
involvement were enrolled of which approximately 50% had a history of pancolitis. Treatment consisted
of 0.1 g, 0.78 g or 1.17 g of oral AVX-470 twice daily for 28 days. Therapy was well tolerated in all
three treatment arms with no serious drug-related incidents. Pharmacokinetic analysis showed no
substantial systemic AVX-470 absorption or the development of antibodies against bovine Ig, which
was a surrogate marker for the immunogenicity of AVX-470. However, stool bovine Ig increased with
increasing dose suggesting that AVX-470 transited through the entire GIT, which is consistent with the
observed GI stability of orally administered Ig [77,78]. Pharmacodynamic analyses were considered
exploratory due to the relatively small study population and short duration of therapy (4 weeks).
Nonetheless, a trend towards a dose-dependent relationship was seen for clinical remission, endoscopic
response and endoscopic remission. In the 3.5-g/day treatment arm, 14% of patients reached clinical
remission as well as endoscopic remission compared to 0% in the placebo group (not powered for
statistical significance). Furthermore, favorable responses in Mayo scores and serum CRP and IL-6 were
observed. Interestingly, the same research group analyzed colonic biopsies of the included patients
in a separate study [107] and found that clinical response was correlated with a reduction in tissue
TNF-α levels and other inflammatory markers. Moreover, it was observed that bovine Ig penetrated
the submucosal tissue of UC patients whether there was visible inflammation or not. However, bovine
Ig did not penetrate into the tissue of healthy volunteers. Of note, bovine Ig was a surrogate marker for
AVX-470, but these results could have been confounded by the consumption of dairy products or beef.
Nonetheless, it shows that an antibody can penetrate into the inflamed mucosa and submucosa in UC
patients. This has also been reported in several colitis animal studies [92,105,109], which is consistent
with this observation.
V565 is a 115 amino acid 12.6 kDa single domain antibody and is also discussed in Section 3. [92,94].
Results from a clinical trial [104] showed that active V565 could be recovered in the ileal fluids of
patients with a terminal ileostomy after oral administration of enteric-coated tablets with a pH threshold
≥ 6. In CD patients, high active V565 concentrations could be recovered in fecal samples. However,
serum levels could not be detected. In UC patients, V565 penetrated the lamina propria and inhibited
the phosphorylation of several proteins involved in inflammatory responses. No serious adverse events
were reported. Though no formal efficacy study was performed, these results show that V565 is stable
during GI transit, can penetrate into the lamina propria of UC patients and exert a pharmacological
effect. This result, together with observations of AVX-470 [107,108] and animal studies [92,105,109],
corroborate the theory that orally administered antibodies penetrate into the inflamed tissues in IBD
and exert a pharmacological effect.
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5. Conclusions
Local TNF-α inhibition in IBD is feasible. Animal studies showed that topical antibody or
nucleotide therapy could penetrate into the inflamed sites of the GIT and exert a pharmacological
effect. This observation was consistent for antibodies that were investigated in clinical studies.
Experimental animal studies showed the feasibility and efficacy of local TNF-α inhibition in IBD
models. Nonetheless, several challenges remain for these experimental therapies due to the relatively
unconventional mechanism of action. For instance, appropriate dose regimens, dose escalation
algorithms, and mechanisms to terminate oligonucleotide as well as prokaryotic therapy should be
available before these therapies reach the clinical settings. Furthermore, methods to evaluate the
site-specific targeting performance of oligonucleotide formulation are of great value since mucosal
concentrations may not always correlate with the intracellular drug concentrations of the targeted cells.
The clinical studies showed the effectiveness of local TNF-α inhibition realized by local injections,
topical treatment or oral therapy. For some patients not responding to conventional therapy, which
included systemic anti-TNF-α therapy, local TNF-α inhibition was effective. However, most clinical
studies were inherently limited, biased, and used a patient unfriendly route of administration.
A prerequisite for adequate therapy and patient compliance is a patient friendly formulation
with the objective to inhibit TNF-α locally. An effective oral formulation targeted to the site of
inflammation meets these requirements. Several formulations discussed in this review aim to achieve
this treatment approach.
The different approaches discussed in this review aimed to target the anti-inflammatory therapy to
the site of inflammation in view of maximizing the local efficacy while minimizing the systemic effects.
Appropriately designed clinical trials are necessary to investigate the efficacy of this approach in IBD.
Additionally, it would be interesting to compare local TNF-α inhibition to gold standard anti-TNF-α
therapies in these trials. These data would give insight into the efficacy and feasibility of local TNF-α
inhibition as well as the mechanism of action of these compounds and TNF-α in IBD.
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